Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Linking clinical registry data with administrative data using indirect identifiers: implementation and validation in the congenital heart surgery population.

Pasquali SK, Jacobs JP, Shook GJ, O'Brien SM, Hall M, Jacobs ML, Welke KF, Gaynor JW, Peterson ED, Shah SS, Li JS.

Am Heart J. 2010 Dec;160(6):1099-104. doi: 10.1016/j.ahj.2010.08.010.

2.

Safety of aprotinin in congenital heart operations: results from a large multicenter database.

Pasquali SK, Hall M, Li JS, Peterson ED, Jaggers J, Lodge AJ, Jacobs JP, Jacobs ML, Shah SS.

Ann Thorac Surg. 2010 Jul;90(1):14-21. doi: 10.1016/j.athoracsur.2010.02.073.

3.

High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.

Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M.

Anesth Analg. 2010 Feb 1;110(2):350-3. doi: 10.1213/ANE.0b013e3181c92b23. Epub 2009 Dec 8.

PMID:
19996135
4.

An empirically based tool for analyzing mortality associated with congenital heart surgery.

O'Brien SM, Clarke DR, Jacobs JP, Jacobs ML, Lacour-Gayet FG, Pizarro C, Welke KF, Maruszewski B, Tobota Z, Miller WJ, Hamilton L, Peterson ED, Mavroudis C, Edwards FH.

J Thorac Cardiovasc Surg. 2009 Nov;138(5):1139-53. doi: 10.1016/j.jtcvs.2009.03.071.

5.

The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis.

Guzzetta NA, Evans FM, Rosenberg ES, Fazlollah TM, Baker MJ, Wilson EC, Kaiser AM, Tosone SR, Miller BE.

Anesth Analg. 2009 Feb;108(2):448-55. doi: 10.1213/ane.0b013e318194007a.

PMID:
19151271
6.

Verification of data in congenital cardiac surgery.

Clarke DR, Breen LS, Jacobs ML, Franklin RC, Tobota Z, Maruszewski B, Jacobs JP.

Cardiol Young. 2008 Dec;18 Suppl 2:177-87. doi: 10.1017/S1047951108002862.

PMID:
19063789
7.

Nomenclature for congenital and paediatric cardiac disease: historical perspectives and The International Pediatric and Congenital Cardiac Code.

Franklin RC, Jacobs JP, Krogmann ON, Béland MJ, Aiello VD, Colan SD, Elliott MJ, William Gaynor J, Kurosawa H, Maruszewski B, Stellin G, Tchervenkov CI, Walters Iii HL, Weinberg P, Anderson RH.

Cardiol Young. 2008 Dec;18 Suppl 2:70-80. doi: 10.1017/S1047951108002795.

PMID:
19063777
8.

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators.

N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

9.

Aprotinin is safe in pediatric patients undergoing cardiac surgery.

Backer CL, Kelle AM, Stewart RD, Suresh SC, Ali FN, Cohn RA, Seshadri R, Mavroudis C.

J Thorac Cardiovasc Surg. 2007 Dec;134(6):1421-6; discussion 1426-8. Epub 2007 Oct 22.

10.

Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial.

Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, Perez R, Brouard M, Milena A, Martinez R, Mora ML.

Crit Care. 2007;11(6):R117.

11.

Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin.

Arnold DM, Fergusson DA, Chan AK, Cook RJ, Fraser GA, Lim W, Blajchman MA, Cook DJ.

Anesth Analg. 2006 Mar;102(3):731-7.

PMID:
16492820
12.

The risk associated with aprotinin in cardiac surgery.

Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.

N Engl J Med. 2006 Jan 26;354(4):353-65.

13.

Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?

Bulutcu FS, Ozbek U, Polat B, Yalçin Y, Karaci AR, Bayindir O.

Paediatr Anaesth. 2005 Jan;15(1):41-6.

PMID:
15649162
14.

Aprotinin reduces operative closure time and blood product use after pediatric bypass.

Costello JM, Backer CL, de Hoyos A, Binns HJ, Mavroudis C.

Ann Thorac Surg. 2003 Apr;75(4):1261-6.

PMID:
12683573
15.

Plasma tranexamic acid concentrations during cardiopulmonary bypass.

Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver WC Jr, Sarpal RS, Oyen LJ, Ereth MH.

Anesth Analg. 2001 May;92(5):1131-6.

PMID:
11323334
16.

High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery.

Tassani P, Augustin N, Barankay A, Braun SL, Zaccaria F, Richter JA.

J Cardiothorac Vasc Anesth. 2000 Dec;14(6):682-6.

PMID:
11139109
17.

Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease.

Chauhan S, Kumar BA, Rao BH, Rao MS, Dubey B, Saxena N, Venugopal P.

Ann Thorac Surg. 2000 Oct;70(4):1308-12.

PMID:
11081890
18.

Reduced inotropic support after aprotinin therapy during pediatric cardiac operations.

Wippermann CF, Schmid FX, Eberle B, Huth RG, Kampmann C, Schranz D, Oelert H.

Ann Thorac Surg. 1999 Jan;67(1):173-6.

PMID:
10086544
19.

Aprotinin improves outcome of single-ventricle palliation.

Tweddell JS, Berger S, Frommelt PC, Pelech AN, Lewis DA, Fedderly RT, Frommelt MA, McManus TS, Mussatto KA, Kessel MW, Litwin SB.

Ann Thorac Surg. 1996 Nov;62(5):1329-35; discussion 1335-6.

PMID:
8893564
20.

Bleeding and use of blood products after heart operations in infants.

Petäjä J, Lundström U, Leijala M, Peltola K, Siimes MA.

J Thorac Cardiovasc Surg. 1995 Mar;109(3):524-9.

Supplemental Content

Support Center